STRATIFYING AUTOIMMUNE RISK IN MPN THERAPY: INDEPENDENT ROLES OF INTERFERON-Α AND RUXOLITINIB WITH PREDICTIVE BIOMARKERS

EHA Library, Guangshuai Teng, 4207885

IMPACT OF RUSFERTIDE ON POLYCYTHEMIA VERA (PV)-RELATED SYMPTOMS AND PATIENT-REPORTED OUTCOME-RELATED ITEMS IN THE RANDOMIZED, DOUBLE-BLIND PHASE 3 VERIFY STUDY

EHA Library, Alessandro Lucchesi, 4207886

POST-MARKETING STUDY OF ROPEGINTERFERON ALFA-2B IN PATIENTS INTOLERANT TO HYDROXYUREA OR WITH A HISTORY OF SKIN CANCER

EHA Library, Tiziano Barbui, 4207890

EARLY-ONSET PHILADELPHIA-NEGATIVE MPN: AGE-DEPENDENT MUTATION DISTRIBUTION AND AGE-INDEPENDENT THROMBOTIC RISK

EHA Library, Olga Demska, 4207891

LONGITUDINAL ANALYSIS OF IRON DEFICIENCY MARKERS IN PATIENTS WITH POLYCYTHEMIA VERA ENROLLED IN THE PROSPECTIVE OBSERVATIONAL REVEAL STUDY

EHA Library, Jamile Shammo, 4207898

HEMATOLOGIC CONTROL AND IMPROVED SAFETY FOLLOWING CROSSOVER FROM ANAGRELIDE TO ROPEGINTERFERON ALFA-2B IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA: DATA FROM THE SURPASS-ET STUDY

EHA Library, Lucia Masarova, 4207900

MEASURABLE RESIDUAL DISEASE IN MYELOFIBROSIS: CLONAL CORRELATES FROM A PROSPECTIVE PHASE II STUDY

EHA Library, Nico Gagelmann, 4207901

RISK FACTORS FOR PROGRESSIVE KIDNEY IMPAIRMENT AMONG PATIENTS WITH POLYCYTHEMIA VERA (PV) ARE RECAPITULATED AND TREATABLE IN MOUSE MODELS OF PV

EHA Library, Brandi Reeves, 4207902

A PHASE 1 STUDY OF THE PRMT5 INHIBITOR AZD3470 IN PATIENTS WITH RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA (PRIMAVERA)

EHA Library, Pier Luigi Zinzani, 4207903

PEMBROLIZUMAB IN CHILDREN AND YOUNG ADULTS WITH LOW-RISK CLASSIC HODGKIN LYMPHOMA WITH SLOW EARLY RESPONSE TO FRONT-LINE CHEMOTHERAPY: UPDATED RESULTS FROM KEYNOTE-667

EHA Library, Kara Kelly, 4207904

VALIDATION OF THE ADVANCED-STAGE HODGKIN LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX (A-HIPI) IN THE GHSG HD21 TRIAL

EHA Library, Hishan Tharmaseelan, 4207905

CHOP/MINICHOP AND TISLELIZUMAB IN ELDERLY PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA (CHL). FIRST REPORT OF THE PHASE II CATER-HL TRIAL (HD12) FROM THE AUSTRALASIAN LYMPHOMA AND LEUKAEMIA GROUP (ALLG).

EHA Library, Tara Cochrane, 4207906

A GERIATRIC RISK SCORE INTEGRATING METABOLIC TUMOR BURDEN AND HOST VULNERABILITY OUTPERFORMS CONVENTIONAL TOOLS AND GUIDES TREATMENT INTENSIFICATION IN OLDER HODGKIN LYMPHOMA PATIENTS

EHA Library, Peiqi Zhao, 4207909

REAL WORLD EFFICACY AND SAFETY COMPARISON OF SALVAGE REGIMENS COMBINING BRENTUXIMAB VEDOTIN AND CHEMOTHERAPY IN SECOND-LINE HODGKIN LYMPHOMA: A LYSA MULTICENTER RETROSPECTIVE STUDY.

EHA Library, Juliette Wencel, 4207910

PROGNOSTIC VALUE OF PET METRICS IN CHILDREN AND YOUNG ADULTS WITH RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA TREATED WITH NIVOLUMAB AND BRENTUXIMAB VEDOTIN ON CHECKMATE 744

EHA Library, Sarah Milgrom, 4207913

PEMBROLIZUMAB (PEMBRO) IN PEDIATRIC PARTICIPANTS WITH HIGH-RISK CLASSIC HODGKIN LYMPHOMA (CHL): AN EXPLORATORY ANALYSIS OF CIRCULATING TUMOR DNA (CTDNA) FROM THE PHASE 2 KEYNOTE-667 STUDY

EHA Library, Christine Mauz-Koerholz, 4207914

REAL-WORLD OUTCOMES OF PEMBROLIZUMAB PLUS GVD AS SALVAGE THERAPY AND BRIDGE TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA: A MULTICENTER GATLA STUDY

EHA Library, Astrid Pavlovsky, 4207915

EXTERNAL VALIDATION OF THE EARLY-STAGE CHL INTERNATIONAL PROGNOSTIC INDEX (E-HIPI) IN A MULTICENTRIC ITALIAN COHORT

EHA Library, Alessandro Cellini, 4207916

ASSOCIATION OF CIRCULATING TUMOUR DNA AND EBV DNA CHARACTERISTICS WITH SURVIVAL OUTCOMES OF CHILDREN AND YOUNG ADULTS WITH HODGKIN LYMPHOMA IN EAST AFRICA

EHA Library, clara chamba, 4207918

SEPARATING THE IMPACT OF POD24 AND TRANSFORMATION IN FOLLICULAR LYMPHOMA: A PROSPECTIVE BIOPSY-CONFIRMED STUDY

EHA Library, Diana Malarikova, 4207919

COMBINATION TREATMENT WITH NOVEL BCL2 INHIBITOR SONROTOCLAX (BGB-11417) AND ZANUBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (R/R MCL): RESULTS FROM A PHASE 1/1B STUDY

EHA Library, Jacob Soumerai, 4207921

A MULTICENTER, PHASE II STUDY OF ORELABRUTINIB-LENALIDOMIDE-RITUXIMAB IN PATIENTS WITH UNTREATED MANTLE CELL LYMPHOMA (POLARIS): EFFICACY, SAFETY, AND BIOMARKER ANALYSES

EHA Library, Xiaohui Wang, 4207927

FLP-R PROGNOSTIC INDEX IN RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA: A COMPARATIVE ANALYSIS WITH MZL-IPI, MALT-IPI AND POD24

EHA Library, Prokop Vodicka, 4207930

PROGNOSTIC VALUE OF PET PARAMETERS IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) TREATED WITH LISOCABTAGENE MARALEUCEL (LISO-CEL): RESULTS FROM THE TRANSCEND FL TRIAL

EHA Library, Anne-Segolene Cottereau, 4207931

THE ZAP TRIAL: FIRST PROSPECTIVE VALIDATION OF AN MRD-ADAPTED, CHEMOTHERAPY-SPARING REGIMEN WITH ZANUBRUTINIB PLUS G-CHOP IN HIGH-RISK FOLLICULAR LYMPHOMA

EHA Library, Peiqi Zhao, 4207932

UPDATED EFFICACY AND SAFETY RESULTS OF ROCBRUTINIB FROM THE PHASE 2 ROCK-1 STUDY IN PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA AND PREVIOUSLY TREATED WITH BTK INHIBITOR

EHA Library, Yuqin Song, 4207933

INCIDENCE OF INFECTIONS IN PATIENTS TREATED WITH RITUXIMAB-BENDAMUSTINE WITH OR WITHOUT ACALABRUTINIB FOR UNTREATED MANTLE CELL LYMPHOMA: ANALYSIS OF THE PHASE 3 ECHO TRIAL

EHA Library, Martin Dreyling, 4207940

FLP-R: A CLINICAL PREDICTION MODEL FOR FOLLICULAR LYMPHOMA PROGNOSIS IN THE RELAPSED/REFRACTORY SETTING

EHA Library, Jennifer Bøgh Jørgensen, 4207942

CLINICAL OUTCOMES AMONG PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA RECEIVING ZANUBRUTINIB OR ACALABRUTINIB IN REAL-WORLD PRACTICE IN THE UNITED STATES

EHA Library, Javier Munoz, 4207946

ORELABRUTINIB COMBINED WITH BENDAMUSTINE-RITUXIMAB OR OBINUTUZUMAB FOLLOWED BY ORELABRUTINIB MAINTENANCE IN UNTREATED MARGINAL ZONE LYMPHOMA (OPTIMIZE): A MULTICENTER, SINGLE-ARM, PHASE II STUDY

EHA Library, Xuewu Zhang, 4207947

INTERPRETABLE MULTIMODAL PET/CT-EHR FUSION VIA MIXTURE-OF-EXPERTS FOR PROGNOSTIC STRATIFICATION IN MANTLE CELL LYMPHOMA: A MULTICENTER STUDY

EHA Library, Chong Jiang, 4207948

LOW-GRADE CRS AND ICANS WITH RONDECABTAGENE AUTOLEUCEL, A DUAL-TARGETING CD19/CD20 CAR T-CELL PRODUCT CANDIDATE, IN PATIENTS WITH LARGE B-CELL LYMPHOMA: UPDATED SAFETY ANALYSIS

EHA Library, Sarah M. Larson, 4207950

FIVE-YEAR FOLLOW-UP OF PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA WHO ACHIEVED A COMPLETE RESPONSE WITH GLOFITAMAB MONOTHERAPY

EHA Library, Krish Patel, 4207951

ZANUBRUTINIB PLUS R-CHOP AS FRONTLINE THERAPY FOR MYD88（L265P）/CD79B-MUTATED (MCD) DIFFUSE LARGE B-CELL LYMPHOMA: A PHASE II STUDY.

EHA Library, Chunmei Yang, 4207952

THE OPTIMATE-TRIAL: AN INVESTIGATOR-INITIATED RANDOMIZED PHASE III STUDY TO OPTIMIZE MATRIX INDUCTION IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA (TRIAL IN PROGRESS)

EHA Library, Gerald Illerhaus, 4207953

IMPACT OF PRIOR LINES OF THERAPY ON PROGRESSION RISK AND POST-FAILURE OVERALL SURVIVAL FOLLOWING AXICABTAGENE CILOLEUCEL OR LISOCABTAGENE MARALEUCEL CAR T-CELLS THERAPY.

EHA Library, Anna Dodero, 4207954

MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN VERSUS RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN LARGE B-CELL LYMPHOMA: UPDATED EFFICACY AND SAFETY FROM THE PHASE 3 SUNMO STUDY INCLUDING IN PATIENT SUBGROUPS

EHA Library, L. Elizabeth Budde, 4207956

TIME-DEFINED PD-1 BLOCKADE DURING EARLY CAR-T CONTRACTION OF IL-7/CCL19–ARMORED CAR-T CELLS IS ASSOCIATED WITH RESPONSE DEEPENING IN HIGH-RISK RELAPSED/REFRACTORY LBCL


LOGO

EHA Library, Lixia Sheng, 4207957

PHASE I/II STUDY OF ZANUBRUTINIB IN COMBINATION WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: INTERIM RESULTS OF THE PHASE II PART

EHA Library, Hyungwoo Cho, 4207960

BIRELENTINIB DEMONSTRATES MANAGEABLE SAFETY PROFILE AND UNIVERSAL ANTITUMOR ACTIVITY ACROSS MOLECULAR SUBTYPES IN DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, lugui qiu, 4207961

HUMANIZED PDX MODELS REVEAL DRUG-REVERSIBLE EPIGENETIC IMMUNE EXCLUSION GOVERNING THERAPY OUTCOME IN DLBCL, ALLOWING PATIENTS STRATIFICATION.

EHA Library, Giovanni Medico, 4207962

ZAMTOCABTAGENE AUTOLEUCEL, A TANDEM CD20-CD19 DIRECTED CAR-T CELL THERAPY IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: CROSSOVER ANALYSIS (THIRD-LINE) FROM THE RANDOMIZED, PIVOTAL DALY 2-EU TRIAL

EHA Library, Peter Vandenberghe, 4207963

SUSTAINED REMISSIONS BEYOND 4 YEARS WITH EPCORITAMAB MONOTHERAPY: LONG-TERM FOLLOW-UP RESULTS FROM THE PIVOTAL EPCORE NHL-1 TRIAL IN PATIENTS WITH RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA

EHA Library, Catherine Thieblemont, 4207965

LOW EXPRESSION OF ZFP36L1 PREDICTS POOR OUTCOMES AND ASSOCIATES WITH MITOCHONDRIAL TRANSLATION PROGRAMS IN DLBCL

EHA Library, Yingyu Dong, 4207968

AXICABTAGENE CILOLEUCEL AS SECOND-LINE TREATMENT IN PATIENTS WITH LATE-RELAPSED LARGE B-CELL LYMPHOMA: INTERIM ANALYSIS OF THE LATE-R CLINICAL TRIAL FROM THE SPANISH LYMPHOMA GROUP GELTAMO

EHA Library, Mariana Bastos-Oreiro, 4207969

POST–CAR-T RELAPSE IN CNS-INVOLVED LYMPHOMA: TREATMENT PATTERNS AND CLINICAL OUTCOMES WITH A FOCUS ON SECOND CAR-T THERAPY

EHA Library, Fan Yang, 4207971

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT AS CONSOLIDATION AFTER CD3XCD20 BISPECIFIC ANTIBODIES IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMAS: AN LWP-CTIWP STUDY ON 52 CASES FROM THE EBMT REGISTRY

EHA Library, Federico Erbella, 4207974

PRIMARY ANALYSIS OF THE POLATUZUMAB VEDOTIN PLUS R-CHP (POLA-R-CHP) COHORT OF FIL-MAB, A PROSPECTIVE, MULTICENTER ITALIAN MULTICOHORT REAL-LIFE STUDY

EHA Library, Marco Ladetto, 4207975

INTRODUCTION OF CAR-T CELL THERAPY DRAMATICALLY IMPROVED OUTCOMES OF PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA RECEIVING SECOND-LINE TREATMENT AT A POPULATION LEVEL

EHA Library, Prokop Vodicka, 4207978

RE‑EVALUATING THE ROLE OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN PRIMARY CNS DIFFUSE LARGE B‑CELL LYMPHOMA IN THE TARGETED‑THERAPY ERA: A PROPENSITY SCORE–MATCHED MULTICENTER REAL‑WORLD STUDY

EHA Library, Mengyuan Liu, 4207980

R-GEMOX+NIVOLUMAB VS R-GEMOX AS 2ND-LINE THERAPY FOR LARGE B-CELL LYMPHOMA IN TRANSPLANT-INELIGIBLE PATIENTS: FINAL ANALYSIS OF THE NIVEAU TRIAL, A PHASE 3 STUDY OF THE AGMT, GLA, HOVON, LYSA AND PLRG

EHA Library, Gerhard Held, 4207981

POLATUZUMAB-BR VS TAFASITAMAB-LENALIDOMIDE IN RELAPSED/REFRACTORY DLBCL: A PROPENSITY SCORE–MATCHED ANALYSIS FROM THE POLISH LYMPHOMA RESEARCH GROUP (PLRG)

EHA Library, Magdalena Olszewska-Szopa, 4207982

EVALUATION OF PELABRESIB (PELA) AS ADD-ON THERAPY TO JANUS KINASE INHIBITOR (JAKI) RUXOLITINIB (RUX) IN MYELOFIBROSIS (MF) PATIENTS: RESULTS FROM ARM 2 OF THE OPEN-LABEL, PHASE 2 MANIFEST STUDY

EHA Library, Marina Kremyanskaya, 4207882

BIOMETRIC DATA SHOWS GREATER ALIGNMENT WITH HAEMATOLOGIC RESULTS THAN SYMPTOM BURDEN IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS – UPDATES FROM THE MYMPNVOICE PATIENT APP

EHA Library, Patrick Harrington, 4207883

SAFETY RESULTS OF THE T2020-004 PHASE I/II TRIAL OF TRAMETINIB AND RISK-STRATIFIED CHEMOTHERAPY FOR CHILDREN WITH NEWLY DIAGNOSED JUVENILE MYELOMONOCYTIC LEUKEMIA: A REPORT FROM THE TACL CONSORTIUM

EHA Library, Elliot Stieglitz, 4207884

IMPACT OF METFORMIN (MET) ON THE INCIDENCE OF SECOND MALIGNANCIES (SMS) IN OLDER PATIENTS WITH POLYCYTHEMIA VERA (PV) OR ESSENTIAL THROMBOCYTHEMIA (ET) IN THE UNITED STATES

EHA Library, Jessica Stempel, 4207887

MODEST INCREASES IN JAK2V617F AND CALR MUTATION ALLELE BURDEN PREDICT ADVERSE OUTCOMES AND ARE ASSOCIATED WITH ANAGRELIDE IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Jennifer O'Sullivan, 4207888

EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B IN JAPANESE PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA:  SUBGROUP ANALYSIS OF THE SURPASS ET TRIAL

EHA Library, Yuka Sugimoto, 4207889

SYMPTOM DISTRIBUTION IN PATIENTS WITH HEREDITARY ALPHA-TRYPTASEMIA (HΑT) AND SYSTEMIC MASTOCYTOSIS (SM): DATA FROM A LARGE GERMAN REGISTRY COHORT

EHA Library, Pia Platthoff, 4207892

TREATMENT PATTERNS AND COMPLICATIONS IN ESSENTIAL THROMBOCYTHEMIA – A POPULATION-BASED STUDY OF 3,234 PATIENTS IN SWEDEN

EHA Library, Anna Ravn Landtblom, 4207893

NEUTROPHIL-LYMPHOCYTE RATIO AND JAK2 V617F ALLELE BURDEN AS PROGNOSTIC INDICATORS OF BIOLOGICAL ACTIVITY AND THROMBOTIC RISK IN POLYCYTHEMIA VERA.

EHA Library, Andrea Bender, 4207894

MULTIPLE TET2 MUTATIONS CONFER INCREASED RISK OF LEUKEMIC TRANSFORMATION IN PATIENTS WITH MYELOFIBROSIS

EHA Library, Jian Huang, 4207895

A PHASE IB STUDY OF 9MW3011, A FIRST-IN-CLASS ANTI-TMPRSS6 ANTIBODY, IN RELAPSED/REFRACTORY PATIENTS WITH POLYCYTHEMIA VERA

EHA Library, Bing LI, 4207896

RESTORE-PV – A PHASE 2 OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE ANTI-TMPRSS6 MONOCLONAL ANTIBODY DISC-3405 IN PARTICIPANTS WITH POLYCYTHEMIA VERA

EHA Library, Naseema Gangat, 4207897

AGE AS A CORE DISEASE MODIFIER: DISTINCT CLINICAL, MOLECULAR, AND PROGNOSTIC LANDSCAPES OF ESSENTIAL THROMBOCYTHEMIA IN ADOLESCENTS AND YOUNG ADULTS

EHA Library, Jian Huang, 4207899

SEX-SPECIFIC CHARACTERISTICS AND OUTCOMES IN NODULAR LYMPHOCYTE-PREDOMINANT HODGKIN LYMPHOMA: AN ANALYSIS FROM THE GERMAN HODGKIN STUDY GROUP

EHA Library, Dennis A. Eichenauer, 4207907

OUTCOME AND PROGNOSTIC VALUE OF PET-2 IN STAGE IV CLASSICAL HODGKIN LYMPHOMA TREATED WITH FRONTLINE BRENTUXIMAB VEDOTIN PLUS AVD: A REAL-WORLD MULTINATIONAL GELTAMO-GATLA STUDY

EHA Library, Jose Ignacio Trucco, 4207908

DURABLE COMPLETE RESPONSES AFTER NIVOLUMAB DISCONTINUATION IN RELAPSED/REFRACTORY CLASSIC HODGKIN LYMPHOMA: SEVEN-YEAR FOLLOW-UP AND RETREATMENT OUTCOMES

EHA Library, Liudmila Fedorova, 4207911

INTERIM RESULTS OF A PET-GUIDED IMMUNE CHECKPOINT INHIBITOR–BASED FIRST-LINE STRATEGY IN ADVANCED-STAGE CLASSICAL HODGKIN LYMPHOMA

EHA Library, Anna Kravtsova, 4207912

SUPERIOR EFFICACY OF BRECADD VS PET-GUIDED ABVD AND BEACOPP IN ADVANCED-STAGE FRONTLINE HODGKIN LYMPHOMA: A MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON OF LONG-TERM FOLLOW-UP DATA OF HD21 STUDY

EHA Library, Fjoralba Kristo, 4207917

RECLASS : REFINEMENT OF MARGINAL ZONE LYMPHOMA CLASSIFICATION AND STAGING IMPROVES PROGNOSTIC DISCRIMINATION IN THE PROSPECTIVE REALYSA COHORT.

EHA Library, Côme Bommier, 4207920

OUTCOMES OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL): FIRST REAL-WORLD DATA FROM THE CIBMTR

EHA Library, Jennifer Huang, 4207923

PROGNOSTIC IMPACT OF FDG-PET–BASED BONE MARROW ASSESSMENT COMPARED WITH CONVENTIONAL HISTOLOGY IN FOLLICULAR LYMPHOMA: A SUBANALYSIS OF THE FIL FOLL12 TRIAL

EHA Library, Giovanni Manfredi Assanto, 4207924

RITUXIMAB (R), GOLCADOMIDE (GOLCA) +/- NIVOLUMAB (N) IN TREATMENT-NAIVE FOLLICULAR LYMPHOMA (FL). PRIMARY RESULTS OF THE INVESTIGATOR-LED RANDOMISED PHASE II TOP-FLOR STUDY.

EHA Library, Eliza Hawkes, 4207925

EO2463 (EO) AN OFF-THE-SHELF MULTI-TARGET PEPTIDE IMMUNOTHERAPY: IN VIVO CD8 T CELL EXPANSION KINETICS CORRELATES WITH EFFICACY IN PATIENTS (PTS) WITH FOLLICULAR (FL) AND MARGINAL ZONE (MZL) LYMPHOMA

EHA Library, Jose C. Villasboas, 4207926

CLONAL FEATURES AND MOLECULAR PREDICTORS OF MRD NEGATIVITY ATTAINMENT IN WALDENSTROM'S MACROGLOBULINEMIA: CLINICAL IMPLICATIONS FOR THERAPEUTIC DE-ESCALATION

EHA Library, Anastasia Vinnikova, 4207928

IMPROVED CAUSE-SPECIFIC SURVIVAL FOR WALDENSTROM MACROGLOBULINEMIA IN THE ERA OF NOVEL THERAPIES

EHA Library, Muhammad Azeem Khan, 4207929

THE EFFICACY AND SAFETY OF OBINUTUZUMAB WITH ZANUBRUTINIB AS FIRST-LINE TREATMENT IN OLDER PATIENTS WITH MANTLE CELL LYMPHOMA

EHA Library, Yanan Zhu, 4207934

CLINICAL OUTCOME AFTER BREXU-CEL THERAPY FAILURE IN MANTLE CELL LYMPHOMAS: AN ANALYSIS OF THE ITALIAN CART-SIE STUDY

EHA Library, Annalisa Chiappella, 4207935

PHASE 3 INMIND STUDY OF TAFASITAMAB PLUS LENALIDOMIDE AND RITUXIMAB FOR RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: CLINICAL CHARACTERISTICS AND OUTCOMES OF PATIENTS RECEIVING SECOND-LINE TREATMENT

EHA Library, Stefano Luminari, 4207936

LONG-TERM FOLLOW-UP OF ORELABRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA

EHA Library, Lijuan Deng, 4207937

IMPACT OF HIV STATUS ON CLINICAL FEATURES AND OUTCOMES OF HHV8-ASSOCIATED MULTICENTRIC CASTLEMAN DISEASE: INSIGHTS FROM A NATIONWIDE GELTAMO STUDY

EHA Library, Gianfranco Lapietra, 4207938

EFFICACY, SAFETY, AND GENETIC ANALYSIS OF ORELABRUTINIB COMBINED WITH RITUXIMAB AS FIRST-LINE SYSTEMIC TREATMENT FOR MARGINAL ZONE LYMPHOMA

EHA Library, Yun Liang, 4207939

TARGETING RESISTANCE TO RITUXIMAB THROUGH FCGRIIB (CD32B) BLOCKADE: BI‑1206 + RITUXIMAB + ACALABRUTINIB SHOWS POWERFUL ACTIVITY IN R/R NHL

EHA Library, Laura Fogliatto, 4207941

LTB-TREAT: A VALIDATED INTERNATIONAL PROGNOSTIC MODEL FOR TIME TO TREATMENT IN LOW TUMOUR BURDEN FL.

EHA Library, Greg Hapgood, 4207943

ZANUBRUTINIB PLUS R-BAP (RITUXIMAB, BENDAMUSTINE, CYTARABINE, AND PREDNISONE) IN PATIENTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA: A PROSPECTIVE, MULTICENTER, INVESTIGATOR-INITIATED STUDY

EHA Library, Jieming Zhang, 4207944

PREDICTIVE ROLE OF POSITRON EMISSION TOMOGRAPHY – COMPUTED TOMOGRAPHY  (PET-CT) IN TREATMENT OF MANTLE CELL LYMPHOMA (MCL) WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS

EHA Library, Vladan Vucinic, 4207945

PHASE 1/2 STUDY OF SONROTOCLAX (BGB-11417) MONOTHERAPY IN BRUTON TYROSINE KINASE (BTK) INHIBITOR-PRETREATED RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (R/R MCL): A CHINESE SUBPOPULATION ANALYSIS

EHA Library, Yuqin Song, 4207949

A DISEASE SPECIFIC PROGNOSTIC SCORE FOR IMMUNODEFICIENCY-ASSOCIATED PRIMARY CNS LYMPHOMA: AN INTERNATIONAL PRIMARY CNS LYMPHOMA COLLABORATIVE GROUP (IPCG) STUDY

EHA Library, Leon D. Kaulen, 4207955

MINIMAL HINGE OPTIMIZATION MARKEDLY ENHANCES DUAL CD19/CD20 CAR T-CELL POTENCY AND YIELDS DURABLE 3-YEAR SURVIVAL IN RELAPSED/REFRACTORY B-CELL LYMPHOMA

EHA Library, Zekai Mao, 4207958

FIRST-LINE ODRONEXTAMAB PLUS CHOP IN DIFFUSE LARGE B-CELL LYMPHOMA: OLYMPIA-3 PART 1B RESULTS

EHA Library, Bastian von Tresckow, 4207959

REAL-WORLD OUTCOMES OF AXICABTAGENE CILOLEUCEL VERSUS NON-CAR-T APPROACHES IN SECOND-LINE FOR PATIENTS WITH LARGE B CELL LYMPHOMA: A SPANISH MULTICENTER GELTAMO-GETH STUDY

EHA Library, Mariana Bastos-Oreiro, 4207964

DEVELOPMENT AND VALIDATION OF CAR-IPI, A MACHINE LEARNING–DERIVED PROGNOSTIC SCORE FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA TREATED WITH ANTI-CD19 CAR T CELLS

EHA Library, Emmanuel Bachy, 4207966

EARLY EXPERIENCE WITH GLOFITAMAB PLUS POLATUZUMAB VEDOTIN AS BRIDGING THERAPY PRIOR TO CD19-DIRECTED CAR T-CELL THERAPY IN R/R B-CELL LYMPHOMA

EHA Library, Thomas Eipe, 4207967

PRELIMINARY RESULTS FROM SHORTEN-CTDNA: MEASURABLE RESIDUAL DISEASE-ADAPTED DE-ESCALATION OF FRONTLINE THERAPY FOR DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Hua-Jay Cherng, 4207970

FEASIBILITY OF PROSPECTIVE REAL-TIME CTDNA MONITORING IN ROUTINE CLINICAL CARE OF DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS

EHA Library, Nathalie Johnson, 4207972

REAL-WORLD COMPARATIVE STUDY OF THE EFFECTIVENESS, SAFETY, AND HEALTH CARE RESOURCE UTILIZATION (HCRU) OF LISOCABTAGENE MARALEUCEL AND BISPECIFICS IN THIRD-LINE OR LATER LARGE B-CELL LYMPHOMA (LBCL)

EHA Library, Narendranath Epperla, 4207973

DENOSUMAB VERSUS ALENDRONATE FOR PREVENTING STEROID-INDUCED OSTEOPOROSIS IN MALIGNANT LYMPHOMA: A MULTICENTER PHASE III TRIAL

EHA Library, Shohei Kikuchi, 4207976

A FULLY OBJECTIVE 3‑VARIABLE PROGNOSTIC SCORE FOR DIFFUSE LARGE B‑CELL LYMPHOMA: DEVELOPMENT AND EXTERNAL VALIDATION IN TWO INDEPENDENT COHORTS TOTALING 776 PATIENTS

EHA Library, Yoshimasa Kamoda, 4207977

LARGE-SCALE REAL-WORLD CLINICAL CHARACTERISTICS AND EFFICACY OF DIFFUSE LARGE B-CELL LYMPHOMA ACROSS DISTINCT MOLECULAR SUBTYPES: INTERIM DATA FROM THE BELIEVE STUDY

EHA Library, Pengpeng Xu, 4207979